{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:01:22Z","timestamp":1762002082707,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ymgmr.2022.100896","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T13:47:22Z","timestamp":1658152042000},"page":"100896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation"],"prefix":"10.1016","volume":"32","author":[{"given":"Mandat","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Skidmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney E.","family":"Croul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Brake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanns","family":"Lochmuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2022.100896_bb0005","series-title":"Pompe Disease: From Basic Science to Therapy Neurotherapeutics","first-page":"928","volume":"15","author":"Kohler","year":"2018"},{"issue":"3","key":"10.1016\/j.ymgmr.2022.100896_bb0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"Gungor","year":"2011","journal-title":"Orphan. J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0020","first-page":"615","article-title":"Spectrum of metabolic myopathies","volume":"2015","author":"Angelini","year":"1852","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgmr.2022.100896_bb0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0030","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Lysomal storage disease 2 Pompe\u2019s disease","volume":"372","author":"Van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"Suppl1","key":"10.1016\/j.ymgmr.2022.100896_bb0035","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1542\/peds.2016-0280D","article-title":"The initial evaluation of patients after positive newborn screening: recommended algorithms leading to a confirmed diagnosis of Pompe disease","volume":"140","author":"Burton","year":"2017","journal-title":"Paediatrics"},{"key":"10.1016\/j.ymgmr.2022.100896_bb0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2014.07.014","article-title":"Methods of diagnosis and patients with Pompe disease: data from the Pompe registry","volume":"113","author":"Kishnani","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1017\/cjn.2016.29","article-title":"Reevaluating muscle biopsies in the diagnosis of Pompe disease: a Corraborative report","volume":"43","author":"Genge","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.21376","article-title":"Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory","volume":"40","author":"Goldstein","year":"2009","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100896_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid (alpha) - glucosidase: Major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2022.100896_bb0060","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alpha in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0070","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"issue":"23","key":"10.1016\/j.ymgmr.2022.100896_bb0075","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2022.100896_bb0080","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/cjn.2016.37","article-title":"Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel","volume":"43","author":"Tarnopolsky","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.ymgmr.2022.100896_bb0085","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.ymgmr.2022.100896_bb0090","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/humu.22108","article-title":"Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants","volume":"33","author":"Kroos","year":"2022","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"Vol. 581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100896_bb0100","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000334398","article-title":"Late onset glycogen storage disease type II: Pitfalls in the diagnosis","volume":"67","author":"Papadimas","year":"2012","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100896_bb0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mus.22296","article-title":"How common is misdiagnosis in late-onset Pompe disease?","volume":"45","author":"Hobson-Webb","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2022.100896_bb0120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ymgme.2013.08.005","article-title":"Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular","volume":"110","author":"Preisler","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymgme.2017.06.007","article-title":"Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme) in 12 patients with advanced late-onset Pompe disease","volume":"122","author":"Papadopoulos","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40248-018-0145-4","article-title":"Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report","volume":"13","author":"Menzella","year":"2018","journal-title":"Multidiscip. Respir. Med."},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100896_bb0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","article-title":"Rate of disease progression during long term follow-up of patients with late onset Pompe disease","volume":"19","author":"Van der Beek","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0140","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late onset Pompe disease: a systemic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.09.001","article-title":"Improvement with ongoing enzyme replacement therapy in advanced late-onset Pompe disease: a case study","volume":"95","author":"Case","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0150","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2022.100896_bb0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","article-title":"Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5 years","volume":"117","author":"Stepien","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","article-title":"Plug I Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up","volume":"39","author":"Deniz Gungor","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10545-011-9393-6","article-title":"Effect of enzyme replacement therapy on five patients with advanced late onset glycogen storage disease type II: a 2 year follow-up study","volume":"35","author":"Furusawa","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100896_bb0170","series-title":"Formulary","first-page":"221","author":"Saskatchewan Ministry of Health","year":"2022"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:22Z","timestamp":1762001542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"alternative-id":["S2214426922000568"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100896","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100896"}}